Canopy Animal Health, Research & Development, Canopy Growth Corporation, Smith Falls, ON, Canada.
Human and Animal Research Program, Canopy Growth Corporation, Smith Falls, ON, Canada.
J Feline Med Surg. 2021 Dec;23(12):1162-1175. doi: 10.1177/1098612X211004215. Epub 2021 Mar 26.
The aim of this study was to determine the safety and tolerability of escalating doses of orally delivered cannabis oils predominant in cannabidiol (CBD), tetrahydrocannabinol (THC), or both CBD and THC in healthy cats.
In this placebo-controlled, blinded study, 20 healthy adult cats were randomized to one of five treatment groups (n = 4 per group): two placebo groups (sunflower oil [SF] or medium-chain triglyceride oil [MCT]), or three plant-derived cannabinoid oil groups (CBD in MCT, THC in MCT or CBD/THC [1.5:1] in SF). Up to 11 escalating doses of each formulation were delivered orally via syringe to fasted subjects, with at least 3 days separating doses. Safety and tolerability were determined from clinical observations, complete blood counts (CBCs) and clinical chemistry. Plasma cannabinoids (CBD, THC) and metabolites (7-COOH-CBD, 11-OH-THC) were assessed.
Titration to maximum doses of 30.5 mg/kg CBD (CBD oil), 41.5 mg/kg THC (THC oil) or 13.0:8.4 mg/kg CBD:THC (CBD/THC oil) was safely achieved in all subjects. All observed adverse events (AEs) were mild, transient and resolved without medical intervention. Gastrointestinal AEs were more common with formulations containing MCT. Constitutional (lethargy, hypothermia), neurologic (ataxia) and ocular (protrusion membrana nictitans) AEs were more common with oils containing THC (CBD/THC and THC oils). There were no clinically significant changes in CBC or clinical chemistry across treatment groups. Higher plasma levels of the cannabinoids and their metabolites following administration of the CBD/THC combination product are suggestive of a pharmacokinetic interaction.
This is the first feline study to explore the safety and tolerability of CBD and THC, alone and in combination, in a controlled research setting. These findings will inform veterinarians of the safety profile of cannabinoids, particularly when considering the potential therapeutic use of CBD in cats or recognizing clinical signs associated with accidental exposure to THC-containing products.
本研究旨在确定在健康猫中递增剂量口服给予以大麻二酚（CBD）、四氢大麻酚（THC）为主或同时含有 CBD 和 THC 的大麻植物衍生油的安全性和耐受性。
在这项安慰剂对照、盲法研究中，将 20 只健康成年猫随机分为五组治疗（每组 4 只）：两组安慰剂组（葵花籽油 [SF] 或中链甘油三酯油 [MCT]），或三组植物衍生大麻素油组（MCT 中的 CBD、MCT 中的 THC 或 SF 中的 CBD/THC [1.5:1]）。通过注射器给禁食的受试猫口服递增剂量的每种制剂，至少间隔 3 天给药。通过临床观察、全血细胞计数（CBC）和临床化学评估安全性和耐受性。评估血浆大麻素（CBD、THC）及其代谢物（7-COOH-CBD、11-OH-THC）。
所有受试猫均安全地达到了最大剂量 30.5mg/kg CBD（CBD 油）、41.5mg/kg THC（THC 油）或 13.0:8.4mg/kg CBD:THC（CBD/THC 油）。所有观察到的不良事件（AE）均为轻度、短暂且无需医疗干预即可缓解。含有 MCT 的制剂更常出现胃肠道 AE。含有 THC 的制剂（CBD/THC 和 THC 油）更常出现全身（嗜睡、体温过低）、神经（共济失调）和眼部（突出瞬膜）AE。治疗组之间 CBC 或临床化学无临床显著变化。给予 CBD/THC 复方产品后，大麻素及其代谢物的血浆水平升高提示存在药代动力学相互作用。
这是第一项在受控研究环境中探索 CBD 和 THC 单独和联合使用的安全性和耐受性的猫科动物研究。这些发现将使兽医了解大麻素的安全性概况，特别是在考虑 CBD 在猫科动物中的潜在治疗用途或识别与意外接触含 THC 产品相关的临床体征时。
